An active post-marketing surveillance study to evaluate the safety and immunogenicity of Zyvac TCV in healthy participants

An active post-marketing surveillance study to evaluate the safety and immunogenicity of Zyvac TCV in healthy participants

Typhoid fever remains a significant public health concern in endemic regions, with increasing antimicrobial resistance heightening the need for preventive strategies such as vaccination. Zyvac-TCV, a typhoid conjugate vaccine developed by Zydus Lifesciences Ltd. is licensed for use across all age gr...

Full description

Saved in:
Bibliographic Details
Main Authors: Sanjay Vasant Mankar, Chintan Patel, Abhishek Chavan, Ravi Modi, Lisa Sarangi, Virendra Nath Tripathi, Dillip Kumar Dash, Jai Prakash Narayan, Sunil Bandgar, N. Ravi Kumar, Vinay Kumar Gill, Munish Kumar Kakkar, Monjori Mitra, Pavankumar Daultani, Ravindra Mittal, Kapil Maithal, Kevinkumar Kansagra, Deven V. Parmar, Trayambak Dutta, Manish Mahajan, Samir Desai
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Typhoid conjugate vaccine (TCV)
anti-Vi IgG seroconversion
geometric mean titers (GMTs)
immunogenicity
post-marketing surveillance
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2550085
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items